Palisade Bio, Inc. (PALI)

NASDAQ: PALI · IEX Real-Time Price · USD
4.295
-0.005 (-0.12%)
Jul 16, 2024, 10:14 AM EDT - Market open
-0.12%
Market Cap 4.03M
Revenue (ttm) n/a
Net Income (ttm) -13.50M
Shares Out 936.40K
EPS (ttm) -23.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,670
Open 4.300
Previous Close 4.300
Day's Range 4.220 - 4.420
52-Week Range 3.820 - 36.600
Beta 1.30
Analysts Strong Buy
Price Target 22.50 (+423.87%)
Earnings Date Aug 9, 2024

About PALI

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company’s lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 9
Stock Exchange NASDAQ
Ticker Symbol PALI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for PALI stock is "Strong Buy" and the 12-month stock price forecast is $22.5.

Price Target
$22.5
(423.87% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstra...

5 days ago - GlobeNewsWire

Palisade Bio to Participate in the Virtual Investor Closing Bell Series

Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company foc...

22 days ago - GlobeNewsWire

Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences

– Collaboration advancing Palisade Bio's precision medicine approach through access to cutting-edge expertise and tools in bioinformatics

25 days ago - GlobeNewsWire

Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108

PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of UC b...

5 weeks ago - GlobeNewsWire

Palisade Bio to Present at the Virtual Investor Pitch Conference

Live video webcast on Monday, June 17 th at 12:00 PM ET Carlsbad, CA, June 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focus...

5 weeks ago - GlobeNewsWire

Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

Data presented at Digestive Disease Week (DDW) 2024 Preclinical data demonstrate PALI-2108 to be safe, effective, and well tolerated PALI-2108 is orally delivered and colon-specific allowing for local...

2 months ago - GlobeNewsWire

Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update

– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end

2 months ago - GlobeNewsWire

Palisade Bio Appoints Margery Fischbein to its Board of Directors

Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally

2 months ago - GlobeNewsWire

Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmun...

2 months ago - GlobeNewsWire

Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

Carlsbad, CA, May 02, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmun...

2 months ago - GlobeNewsWire

Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) before year end

2 months ago - GlobeNewsWire

Palisade Bio stock rallies on Strand Life Sciences partnership

Palisade Bio Inc (NASDAQ: PALI) opened roughly 50% up on Tuesday after teaming up with Strand Life Sciences.  Here's what it means for Palisade Bio stock The strategic collaboration puts its patient d...

2 months ago - Invezz

Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach

– Collaboration grants Palisade Bio access to cutting-edge expertise and tools in bioinformatics – Partnership marks a significant value-driving milestone in Palisade Bio's mission to redefine UC trea...

3 months ago - GlobeNewsWire

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' Stool

Company continues advancing ongoing development of targeted therapies for ulcerative colitis (UC) Carlsbad, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade”, “Pali...

3 months ago - GlobeNewsWire

Palisade Bio to Participate in the Virtual Investor Lunch Break Event

– Live webcast with members of Palisade Bio management on Tuesday, April 16 th at 12:00 PM ET

3 months ago - GlobeNewsWire

Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn's & Colitis™

– PALI-2108 in development for the treatment of moderate-to-severe ulcerative colitis (UC) advancing towards Phase 1 clinical study before year end

3 months ago - GlobeNewsWire

Palisade Bio Announces 1-for-15 Reverse Stock Split

Carlsbad, CA, April 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel...

3 months ago - GlobeNewsWire

Palisade Bio to Present at Digestive Disease Week (DDW) 2024

Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chron...

5 months ago - GlobeNewsWire

Palisade Bio Provides Corporate Update and Reiterates Guidance

– Company announces strategic streamlining of Board to align with the current state of clinical development and corporate vision

5 months ago - GlobeNewsWire

Correction Notice of Palisade Bio's Press Release Announcing the Appointment of Clinical Advisory Board Members

Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.   (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chro...

5 months ago - GlobeNewsWire

Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders

Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chron...

5 months ago - GlobeNewsWire

Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn's & Colitis Congress

– Preclinical data demonstrated PALI-2108 to be safe and well tolerated – PALI-2108 is orally delivered and colon activated allowing for local activity with low systemic exposure – Company advancing P...

6 months ago - GlobeNewsWire

Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn's and Colitis Foundation for Development of PALI-2108

- Company's co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding as part of previously announced grant from the US Crohn's and Colitis Foundation

7 months ago - GlobeNewsWire

Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook

– Transformational transaction jumpstarts development pipeline into high-value inflammatory bowel disease (IBD) market

8 months ago - GlobeNewsWire

Palisade Bio to Participate at the Virtual Investor Ask the CEO Conference

Live moderated webcast with J.D. Finley, Chief Executive Officer of Palisade Bio on Wednesday, October 25 th at 2:00 PM ET

9 months ago - GlobeNewsWire